ADRB2 and respiratory system disorder: Nevertheless, although salbutamol is approved in the clinic for the treatment of respiratory diseases, it is unlikely that conventional tissue-unspecific ADRB2 agonism will be applied to treat cardiometabolic pathophysiology because of common cardiovascular side effects (i.e., increase in heart rate, blood pressure, and tremors).